Zhitong Finance App News, Zhongfu Technology (300692.SZ) announced that the company's wholly-owned subsidiary Zhongfu Junke Zhengyuan (Anhui) Biomedical Technology Co., Ltd. (“Zhongfu Zhengyuan”) and Junke Zhengyuan (Beijing) Pharmaceutical Research Co., Ltd. (“Junke Zhengyuan”) and related parties intend to sign the “Equity Transfer Agreement” and its supplementary agreements to acquire control of Junke Zhengyuan and its integrated CRO assets. The acquisition capital is 1 billion yuan, which is funded through a combination of its own capital, external institutional investment, and bank mergers and acquisitions.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.